On March 2, 2021 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, reported that members of Transgene’s management and scientific team have been invited to participate at upcoming (virtual) scientific conferences (Press release, Transgene, MAR 2, 2021, View Source [SID1234575953]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

– ESMO (Free ESMO Whitepaper) Targeted Anticancer Therapies Congress 2021 which will take place March 2-4:

Éric Quéméneur, Executive Vice President and Chief Scientific Officer (CSO), will be speaking in the session ‘Where next with Oncolytics’ about Antibody armed oncolytic viruses (ID 42)

Date & Time: March 3rd at 4.20pm (CET)

– Royal Society Meeting on ‘Immuno-oncology: How to get the immune system to beat cancer’ which will take place March 24-25:

This Royal Society meeting will explore immuno-oncology therapies – both current and recent technologies. Eric Quéméneur will participate in the immuno-oncology breakthroughs session.

Date & Time: March 24th at 3.50pm (GMT)

– 4th Annual European Neoantigen Summit which will take place April 20-22:

Kaidre Bendjama, Project Leader, Personalized Cancer Vaccines, will be speaking about TG4050: Viral immunotherapy meets AI technology

Date & Time: April 22nd at 1pm (CET)